Advertisement
ALNY or INSM or PFE
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Insmed (INSM) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- ALNY delivered robust 2025 revenue growth of 81% to nearly $3B, driven by TTR franchise expansion, though shares faced recent pressure amid high valuation at 139x P/E.
- INSM reported 2025 revenue of $606M (up 67%), bolstered by BRINSUPRI launch, but remains unprofitable with market cap around $31B and YTD decline.
- PFE maintains scale with $62.6B trailing revenue and 6.3% dividend yield, yet grapples with post-COVID pipeline scrutiny and modest YTD gains.
- Biotech peers ALNY and INSM show higher growth potential versus stable large-cap PFE, with relative performance favoring momentum in rare disease therapies.
- Recent catalysts include ALNY's Tenaya collaboration and INSM's product launches, contrasting PFE's oncology/dermatology trial progress.
- Valuation sensitivity highest for growth-oriented ALNY and INSM, with PFE offering defensive appeal amid market volatility.
Introduction
This stock comparison examines ALNY, INSM, and PFE in the biotech and pharmaceutical sectors, highlighting contrasts in growth trajectories, revenue scales, and market positioning. ALNY pioneers RNAi therapeutics for rare genetic diseases, INSM targets serious pulmonary conditions, and PFE spans broad biopharma portfolios. Traders seeking momentum in innovative therapies and investors eyeing stability or dividends may find value in analyzing their recent performance, pipeline catalysts, and relative valuations amid evolving sector dynamics like regulatory approvals and reimbursement wins.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, focuses on rare genetic, cardio-metabolic, and other diseases. Its portfolio includes AMVUTTRA and ONPATTRO for hATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, with collaborations alongside Regeneron, Novartis, and others. In recent market activity, shares traded around $322 with a $42.8B market cap, reflecting YTD declines amid broader biotech volatility but strong 1-year gains of 33%. Sentiment has been influenced by preliminary 2025 net product revenues of nearly $3B (81% growth, led by 151% TTR surge) and Q4 results showing $1.09B revenue. Key developments include a $1.23B Tenaya collaboration for cardiovascular targets and Canadian reimbursement for AMVUTTRA, supporting pipeline momentum despite elevated 139x P/E.
INSM Overview and Recent Performance
Insmed Incorporated develops therapies for serious rare diseases, emphasizing respiratory conditions. Its lead product ARIKAYCE treats refractory nontuberculous mycobacterial lung infections, while BRINSUPRI (brensocatib) targets non-cystic fibrosis bronchiectasis, recently approved in the US and EU. The pipeline advances TPIP for pulmonary hypertension and other gene therapies. Shares hovered near $144 with a $31B market cap, posting YTD losses after strong 1-year performance over 95%. Recent weeks saw revenue hit $606M in 2025 (67% growth) from BRINSUPRI and ARIKAYCE launches, ending the year with $1.4B cash. Guidance projects 2026 BRINSUPRI sales exceeding $1B and ARIKAYCE at $450M-$470M, bolstering sentiment despite ongoing losses and unprofitability.
PFE Overview and Recent Performance
Pfizer Inc., a global biopharma giant founded in 1849, operates across oncology, vaccines, rare diseases, and inflammation via segments like Biopharma. Key products include Eliquis, Prevnar, Ibrance, and Vyndaqel family, with collaborations including BioNTech. Trading around $27 with a $154B market cap and 6.3% dividend yield, shares showed modest YTD gains amid post-COVID adjustments. Trailing revenue reached $62.6B, with Q4 at $17.6B. Recent activity features positive Phase 2 data for a trispecific antibody in atopic dermatitis, full FDA approval for BRAFTOVI in colorectal cancer, and PADCEV+Keytruda progress in bladder cancer. Patent and pipeline concerns have tempered sentiment, yet analysts note potential undervaluation.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from hundreds available, each trading thousands of tickers with diverse strategies, timeframes like 5min to 60min, and styles from trend-following to hedging. Only those excelling in current conditions—such as sector rotations in semiconductors, aerospace, and biotech—earn spots, often boasting annualized returns up to +227%, win rates of 70-80%, and profit factors exceeding 2.5. Examples include bots with +132% annualized on 25 tickers (61% win rate), +102% on SOXL (70% win rate), and +95% on AeroDefense (72% win rate). These bots leverage technical and fundamental analysis for real-time signals and risk management. Explore Tickeron’s full suite to identify suitable options for today’s market.
Head-to-Head Comparison
ALNY and INSM emphasize rare disease innovation—RNAi and respiratory therapies—driving 81% and 67% revenue growth, respectively, versus PFE’s diversified model with stable but slower expansion. Momentum favors biotechs amid catalysts like collaborations and approvals, though ALNY’s 139x P/E contrasts PFE’s 20x, highlighting valuation trade-offs. Risk profiles differ: high-beta INSM (1.03) and ALNY (0.88) expose to trial volatility, while low-beta PFE (0.42) offers dividend stability. Sector exposure aligns in biotech/pharma, but sentiment tilts toward growth peers’ catalysts over PFE’s scale amid patent pressures.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY for its trend consistency in RNAi leadership, robust revenue acceleration, and fresh cardiovascular catalysts positioning it ahead in relative biotech momentum. While INSM shows strong launch traction and PFE provides stability, ALNY’s observable growth drivers suggest higher probabilistic outperformance in the near term, barring execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- INSM’s FA Score: 0 green, 5 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while INSM’s TA Score has 3 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- INSM’s TA Score: 3 bullish, 6 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while INSM (@Biotechnology) price change was -6.67% , and PFE (@Pharmaceuticals: Major) price fluctuated +2.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
INSM is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | INSM | PFE | |
| Capitalization | 41.3B | 31.2B | 157B |
| EBITDA | 631M | -1.18B | 16.8B |
| Gain YTD | -22.127 | -16.985 | 12.537 |
| P/E Ratio | 132.90 | N/A | 20.26 |
| Revenue | 3.71B | 606M | 62.6B |
| Total Cash | 2.91B | 1.43B | 13.6B |
| Total Debt | 1.28B | 587M | 64B |
ALNY | INSM | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 68 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 76 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 53 | 37 | 100 | |
SMR RATING 1..100 | 15 | 100 | 74 | |
PRICE GROWTH RATING 1..100 | 62 | 49 | 27 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (76) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (94) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INSM’s and somewhat faster than ALNY’s over the last 12 months.
INSM's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as ALNY (53) in the Biotechnology industry, and is somewhat better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that INSM's stock grew similarly to ALNY’s and somewhat faster than PFE’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for PFE (74) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that ALNY's stock grew somewhat faster than PFE’s and significantly faster than INSM’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as INSM (49) in the Biotechnology industry, and is somewhat better than the same rating for ALNY (62) in the Biotechnology industry. This means that PFE's stock grew similarly to INSM’s and somewhat faster than ALNY’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for INSM (100) in the Biotechnology industry, and is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that PFE's stock grew significantly faster than INSM’s and significantly faster than ALNY’s over the last 12 months.
| ALNY | INSM | PFE | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 78% | 3 days ago 66% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 74% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 66% | 3 days ago 55% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 72% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 74% | 3 days ago 51% |
| Advances ODDS (%) | 6 days ago 76% | 19 days ago 71% | 3 days ago 56% |
| Declines ODDS (%) | 3 days ago 66% | 4 days ago 73% | 10 days ago 57% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 70% | 3 days ago 52% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 84% | 3 days ago 52% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.25% | ||
| MRK - PFE | 66% Loosely correlated | +3.13% | ||
| BMY - PFE | 64% Loosely correlated | +2.05% | ||
| BIIB - PFE | 61% Loosely correlated | +0.76% | ||
| AMGN - PFE | 58% Loosely correlated | +1.69% | ||
| NVS - PFE | 54% Loosely correlated | +1.50% | ||
More | ||||